PIERIS PHARMACEUTICALS INC (PIRS)
US7207952026 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning!
3 Doomed Biotech Stocks Destined for Disaster
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.